TrialLancet (London, England)2021

Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.

Anthony R Mato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.